Reese Harry, PhD’s Post

Building causal hypotheses in drug discovery 🎥🤔 If you missed last week's panel discussion with our own Nicola McCarthy and Namshik Han, and Biorelate's Ben Sidders and Daniel Jamieson, you can now view the recording online! Where are the opportunities to use AI and data driven approaches to create more robust models for developing actionable hypotheses? How can biopharma make better use of data for developing mechanistic rationales that will improve drug discovery outcomes for drug developers and patients? Join the discussion by clicking here 👉 https://lnkd.in/eZsq-25A

The world of oligonucleotide therapeutics can feel like you’re in uncharted territory. Cytiva can be your guide. Learn what you need to know in our brand-new oligo infographic – everything from future-proofing to synthesis, purification, and filtration. https://lnkd.in/dES3fw2F #oligos #nucleicacids #oligonucleotides #genomicmedicine

Following a truly insight-rich discussion last week with Nicola McCarthy and Namshik Han of the Milner Therapeutics Institute and Biorelate's CSO Ben Sidders, you can now access the recorded webinar >> https://lnkd.in/eZsq-25A #drugdiscovery #artificialintelligence #bioinformatics

Kesmalea is proud to welcome Rob Johnson as CEO! Fresh from leading Adrestia Therapeutics (acquired by Insmed, Inc.), Rob will take the helm as we build a pipeline of oral, CNS penetrant targeted protein degrader therapeutics. These attributes are difficult to achieve for most large degraders today, but Kesmalea's SELFTAC platform was created to transform large degraders into small molecules through a self-assembling linker technology. By combining the favorable attributes of small molecules with the versatility and power of protein degradation, our goal is to bring a new class of SELFTAC degraders to patients. Read more in our press release: https://lnkd.in/e9ieuamh #biotech #CEO #therapeutics #PROTAC

Check out the latest biotech industry news, from new sequencers and assays for drug optimization to the increasing interest in extracellular vesicles and the finances behind biotech >>> https://lnkd.in/eXTx2v8B Thermo Fisher Scientific, PacBio, Rousselot, Cytek Biosciences, Mursla Bio and Indaptus Therapeutics, Inc.

🌟 We are proud to sponsor NCI SBIR Showcase Company Saros Therapeutics at Biotech Showcase during JPM Healthcare Week. Saros will be presenting their groundbreaking nanoparticle technology during the event. 📅 Saros Therapeutics: Presentation on Tuesday, January 14 ⏰ 11:45 AM PT 📍 Room Franciscan-B 🌐 Saros Therapeutics is revolutionizing cancer and autoimmune disease treatments with its proprietary Saros metallo-nanoparticle platform. This technology safely targets innate immune cells, offering a potent and less toxic alternative to existing formulations. Saros is paving the way for safer and more effective therapies, starting with STING activation in solid tumors. With robust efficacy data, a wide therapeutic index, scalable manufacturing, and an experienced team, the company is raising capital to complete IND filing and begin a first-in-human trial. More about the science: https://lnkd.in/gUBUWDG9 Jennifer Chadwick Matt Martin #BiotechShowcase #SarosTherapeutics #Innovation #Healthcare #CancerTherapy #Nanoparticles #Biotech #LifeSciences

#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/dcFuBP5F #Biotech #Oligonucleotides #EndosomalEscape

Watch this video to see how you can quickly and efficiently determine the melting temperature of biomolecules using the TM Analysis System, an amazing tool that can accelerate the development process and improve the quality of oligonucleotide therapeutics. #biomolecules #oligonucleotides #spectroscopy #analyticalinstruments #shimadzu Learn more about the system here: https://bit.ly/4hyKHKT

#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/dcFuBP5F #Biotech #Oligonucleotides #EndosomalEscape

#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/dcFuBP5F #Biotech #Oligonucleotides #EndosomalEscape